Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The G-CSF Produces Long-Term Changes in Gene and Mirnas Expression Profiles in CD34+ From Healthy Donors

Alicia Báez, Concepción Prats-Martín, M.D, Isabel Álvarez-Laderas, Estefania Garcia, Luis Ignacio Sanchez-Abarca, Ph.D., Beatriz Martin-Antonio, Ph.D., Alvaro Urbano-Ispizua, MD, Jose Antonio Pérez Simón, MD, PhD

Blood (2012) 120 (21): 588.

https://doi.org/10.1182/blood.V120.21.588.588

Published: 2012

Journal Articles

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Cristina Calderón, MD, Jose F Falantes, MD, Francisco Márquez-Malaver, MD, Jose González, MD, PhD, Maria Luz Martino, MD, Isabel Montero, MD, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2012) 120 (21): 4955.

https://doi.org/10.1182/blood.V120.21.4955.4955

Published: 2012

Journal Articles

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Jose F Falantes, MD, Cristina Calderón, MD, Ildefonso Espigado, MD, PhD, Dora Alonso, MD, Antonio Martín Noya, MD, PhD, Estrella Carrillo, MD, Maria Luz Martino, MD, Isabel Montero, MD, Jose González, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2011) 118 (21): 1730.

https://doi.org/10.1182/blood.V118.21.1730.1730

Published: 2011

Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes

Blood (2011) 118 (21): 4986.

https://doi.org/10.1182/blood.V118.21.4986.4986

Published: 2011

Journal Articles

Both Expanded and Uncultured Mesenchymal Stem Cells from MDS Patients Are Genomically Abnormal, Showing a Specific Genetic Profile for the 5q- Syndrome.

Olga López Villar, MD, Juan LuíS. García, PhD, Fermín. M Sánchez Guijo, MD, PhD, Cristina Robledo, Pilar Hernandez Campo, PhD, Maria Diez Campelo, MD, PhD, Sandra Muntion, Jose Antonio Pérez Simón, MD, PhD, J.F. San Miguel, MD, PhD, MaríA. Consuelo Del Cañizo, MD, PhD

Blood (2008) 112 (11): 1650.

https://doi.org/10.1182/blood.V112.11.1650.1650

Published: 2008

NARROW

The G-CSF Produces Long-Term Changes in Gene and Mirnas Expression Profiles in CD34+ From Healthy Donors

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Both Expanded and Uncultured Mesenchymal Stem Cells from MDS Patients Are Genomically Abnormal, Showing a Specific Genetic Profile for the 5q- Syndrome.

Email alerts

ASH Publications

American Society of Hematology

The G-CSF Produces Long-Term Changes in Gene and Mirnas Expression Profiles in CD34+ From Healthy Donors

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Both Expanded and Uncultured Mesenchymal Stem Cells from MDS Patients Are Genomically Abnormal, Showing a Specific Genetic Profile for the 5q- Syndrome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only